An opportunity to test your National Patient Safety Alert process in relation to the guidance on GLP-1 prescribing

 

A National Patient Safety Alert was issued on 18 July relating to GLP-1 receptor agonists (RAs). The alert outlines actions for prescribers:

1. Only prescribe GLP-1 RAs for licensed indications – further details here
2. Do not initiate GLP-1 RAs for new patients
3. Discuss stopping GLP-1 RA treatment with patients in whom it has not been sufficiently effective (see NICE NG28)
4. Do not switch to alternative GLP-1 RAs or alternative strength preparations. Do not double up lower doses.
5. Use the principles of shared decision making where an alternative agent needs to be considered.

If the actions as a result of this alert have been captured, implemented and documented then your process is working well. If not then now is a great time to address this before a CQC inspection.

 

if you want to talk this through with a supportive community head over to our Facebook group :

https://www.facebook.com/groups/254788070091440/

Please refer to the dedicated Specialist Pharmacy Service page for further updates around supply.